Pregnancy

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08,…

4 months ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…

4 months ago

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…

4 months ago

Revolutionary AI-Driven Medtech Platform Changes the Way Patients Receive Quality Healthcare in the UK

LONDON, UK / ACCESSWIRE / February 6, 2024 / Access to efficient and convenient healthcare is vital in order to…

4 months ago

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks.…

4 months ago

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks.…

4 months ago

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products

Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide…

4 months ago

Corporate Update on Clinical Evaluation of MedMira’s Products

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update…

4 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize…

4 months ago